

TABLE 181: TREATMENT-EXPERIENCED SVR GENOTYPE 4 NON-CIRRHOTIC WITH PEARL-I STUDY ADDED: ODDS RATIOS, RELATIVE RISKS, AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + RBV24	SOF12 + RBV12	1.28 (0.65 to 1.80)	18.25 (−23.26 to 41.13)
DCV24 + ASU24 + PR24		1.48 (1.12 to 1.97)	30.62 (8.48 to 47.67)
PAR/RIT12 + OMB12 + RBV12		1.52 (1.22 to 2.01)	33.14 (16.45 to 49.27)
DCV24 + ASU24 + PR24	SOF24 + RBV24	1.14 (0.85 to 2.26)	11.80 (−13.97 to 53.31)
PAR/RIT12 + OMB12 + RBV12		1.17 (0.95 to 2.32)	14.30 (−4.57 to 55.51)
PAR/RIT12 + OMB12 + RBV12	DCV24 + ASU24 + PR24	1.02 (0.89 to 1.30)	1.85 (−10.33 to 22.53)
Random effect model	Residual deviance	5.64 vs. 6 data points	
	Deviance information criteria	26.51	
Fixed effect model	Residual deviance	5.738 vs. 6 data points	
	Deviance information criteria	26.686	

CrI = credible interval; DCV = daclatasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference; RIT = ritonavir; RR = relative risk; SOF = sofosbuvir; SVR = sustained virologic response; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.